Spero Therapeutics appoints William Ho to board as Patrick Vink resigns

Spero Therapeutics, Inc.

Patrick Vink, M.D., resigned from Spero's board effective Nov. 10, 2026, including roles as Nominating and Corporate Governance Committee chair and Compensation Committee member.
The company said Vink's resignation was not due to any dispute or disagreement and thanked him for 11 years of service.
William Ho, M.D., Ph.D., was appointed Class II director effective Nov. 10, 2026, and will serve on the Development Committee.
Ho will receive a $40,000 annual board retainer, $5,000 committee retainer and an option for 100,000 shares vesting monthly over one year.
Ho was RAPT Therapeutics' chief medical officer from 2015 to December 2025; the filing cites RAPT's $2.2 billion acquisition by GSK finalized in March 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.